Oncologic Drug QoL Data Useful After Treatment Failure - FDA Cmte.
Executive Summary
Quality of life assessments should be collected even after treatment failure, a subcommittee of FDA's Oncologic Drugs Advisory Committee suggested at a Feb. 10 meeting in Bethesda, Md.
You may also be interested in...
Aeterna Neovastat Will Be 12th Antiangiogenesis Drug To Reach Phase III
Aeterna Labs' Neovastat will begin patient enrollment for a Phase III clinical trial in non-small cell lung cancer in March, CEO Eric Dupont reported Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011